These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1428236)

  • 1. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells.
    Silvestrini R; Zaffaroni N; Villa R; Orlandi L; Costa A
    Int J Cancer; 1992 Nov; 52(5):813-7. PubMed ID: 1428236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of cisplatin cytotoxicity by lonidamine in primary cultures of human ovarian cancer.
    Orlandi L; Zaffaroni N; Gornati D; Veneroni S; Silvestrini R
    Anticancer Res; 1994; 14(3A):1161-4. PubMed ID: 8074467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells.
    Silvestrini R; Gornati D; Zaffaroni N; Bearzatto A; De Marco C
    Breast Cancer Res Treat; 1997 Jan; 42(2):103-12. PubMed ID: 9138599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis.
    Orlandi L; Zaffaroni N; Bearzatto A; Villa R; De Marco C; Silvestrini R
    Int J Cancer; 1998 Oct; 78(3):377-84. PubMed ID: 9766575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
    De Lena M; Lorusso V; Bottalico C; Brandi M; De Mitrio A; Catino A; Guida M; Latorre A; Leone B; Vallejo C; Gargano G
    J Clin Oncol; 1997 Oct; 15(10):3208-13. PubMed ID: 9336357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs.
    Gornati D; Zaffaroni N; Villa R; De Marco C; Silvestrini R
    Anticancer Drugs; 1997 Jun; 8(5):509-16. PubMed ID: 9215615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
    Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
    Rosbe KW; Brann TW; Holden SA; Teicher BA; Frei E
    Cancer Chemother Pharmacol; 1989; 25(1):32-6. PubMed ID: 2590999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor.
    Perez RP; Handel LM; Hamilton TC
    Gynecol Oncol; 1992 Jul; 46(1):82-7. PubMed ID: 1634144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts.
    De Cesare M; Pratesi G; Giusti A; Polizzi D; Zunino F
    Br J Cancer; 1998; 77(3):434-9. PubMed ID: 9472640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells.
    Villa R; Orlandi L; Berruti A; Dogliotti L; Zaffaroni N
    Int J Oncol; 1999 Jan; 14(1):133-8. PubMed ID: 9863019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer.
    Bottalico C; Lorusso V; Brandi M; Micelli G; Rella CA; Coviello M; Atlante AM; Quaranta M; De Lena M
    Anticancer Res; 1996; 16(6B):3865-9. PubMed ID: 9042272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
    Di Cosimo S; Ferretti G; Papaldo P; Carlini P; Fabi A; Cognetti F
    Drugs Today (Barc); 2003 Mar; 39(3):157-74. PubMed ID: 12730701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
    Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
    Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft.
    Pratesi G; De Cesare M; Zunino F
    Cancer Chemother Pharmacol; 1996; 38(2):123-8. PubMed ID: 8616901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro.
    Ning SC; Hahn GM
    Cancer Res; 1990 Dec; 50(24):7867-70. PubMed ID: 2253227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells.
    Villa R; Zaffaroni N; Orlandi L; Bearzatto A; Costa A; Silvestrini R
    Eur J Cancer; 1994; 30A(10):1534-40. PubMed ID: 7833114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of alkylating agents by lonidamine in vivo.
    Teicher BA; Holden SA; Herman TS; Frei E
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines.
    Brown R; Clugston C; Burns P; Edlin A; Vasey P; Vojtĕsek B; Kaye SB
    Int J Cancer; 1993 Oct; 55(4):678-84. PubMed ID: 8406999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
    Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.